- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06090578
TabCAT Brain Health Assessment in Primary Care
October 20, 2023 updated by: University of California, San Francisco
A Pragmatic Trial of the TabCAT Brain Health Assessment for the Detection of Cognitive Impairment in Primary Care
Efficient and user-friendly paradigms to detect cognitive impairment, including dementia are needed in primary care.
The TabCAT Brain Health Assessment accurately detects cognitive impairment via an appealing tablet interface with automated scoring and EMR integration.
This study will evaluate the effectiveness of the paradigm on detection rates and other brain health outcomes via a pragmatic cluster randomized trial in 26 Kaiser Southern California primary care clinics.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Twenty-six Kaiser Permanente Southern California (KPSC) primary care clinics will be randomized in two waves to receive either the TabCAT-BHA paradigm or usual care.
Clinics have been matched in pairs by number of providers, median panel size, the racial/ethnic makeup of the patient panel, baseline rates of cognitive impairment diagnosis, rates of telehealth encounters, and percentage of members who are 65+ in the practice.
The trial will be conducted over two 18-month waves, with six intervention practices in the first wave and seven intervention practices starting in the second wave.
All patients seen at least once across these 26 practices will be included in the trial and the primary analyses will use data extracted from the EMR.
Patients in the intervention practices will receive care in accordance with the TabCAT-BHA paradigm whereas patients in the control practices will continue with usual care workflows.
The intervention will include a 6-month startup period during which the research team will partner with the physician leads to adapt the paradigm workflows to each practice and onboard the PCPs, and then a 12-month steady state period when effectiveness on the primary and secondary outcomes will be measured.
During the TabCAT-BHA paradigm intervention, pragmatically, primary care providers concerned that their patients are exhibiting signs of cognitive decline will refer them to clinical research associates located in the primary care clinics who will then perform the TabCAT-BHA tablet-based test either on the spot or as a scheduled procedure visit.
The tablet-based test provides an automated scoring report that includes guidance for providers to identify reversible causes of cognitive impairment, involving a care partner, diagnostic disclosure, community and educational resources, and specialty referral including the option to refer the patient for a "Brain Health Consultation" telephone call with a study nurse or social worker.
Study Type
Interventional
Enrollment (Estimated)
180000
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Collette Goode, BS
- Phone Number: 415-514-0881
- Email: collette.goode@ucsf.edu
Study Contact Backup
- Name: Katherine Possin, PhD
- Phone Number: 415-476-1889
- Email: katherine.possin@ucsf.edu
Study Locations
-
-
California
-
Pasadena, California, United States, 91101
- Recruiting
- Kaiser Permanente Southern California Department of Research & Evaluation
-
Contact:
- Huong Q Nguyen, PhD
- Phone Number: 626-773-0873
- Email: huong.q2.nguyen@kp.org
-
Contact:
- Mayra Macias
- Phone Number: 626-344-6667
- Email: mayra.macias@kp.org
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patient with at least one encounter at an intervention clinic during the intervention period
- Age 18+ (limited to 65+ for primary analyses)
Exclusion Criteria:
- Patients under the age of 18.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TabCAT-Brain Health Assessment
Primary care providers concerned that their patients are exhibiting signs of cognitive decline based on patient, informant (family), or provider concerns will refer them for a TabCAT-BHA assessment and follow-up care.
|
Primary care providers concerned that their patients are exhibiting signs of cognitive decline will refer them to clinical associates located in the clinics who will then perform the TabCAT-BHA tablet-based test either on the spot or as a scheduled procedure visit.
The TabCAT-BHA paradigm comprises 7-10 minutes of tablet-based testing and an optional 3-minute self-administered informant survey captures behavioral symptoms and change from baseline.
The results are available to the PCP in the EMR along with turnkey guidance to evaluate for reversible causes, identify and involve a care partner, make and disclose diagnosis, provide community and educational resources, and make medical referrals as appropriate.
The paradigm also includes an optional "Brain Health Consultation," a telephone encounter with a dementia expert nurse or social worker to help address the gaps in care immediately following PCP diagnosis of MCI or dementia.
|
No Intervention: Usual Care
Patients in the control practices will continue with usual care workflows.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The rate of patients with at least one cognitive impairment diagnosis documented in the medical record by any primary care provider during the 12-month steady state period at the clinic.
Time Frame: During the 12-month steady state period
|
Rate is out of all patients with an encounter during the steady state period at the clinic.
The primary analyses for all outcomes are limited to ages 65+.
The list of cognitive impairment diagnoses are published in the supplement of PMID: 35124639.
|
During the 12-month steady state period
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The rate of patients who have a documented standardized cognitive assessment performed in the primary care clinic within 4 months of an incident cognitive impairment diagnosis.
Time Frame: During the 12-month steady state period
|
Rate is out of all patients with an encounter at the clinic during the 12-month steady state period and an incident cognitive impairment diagnosis.
The window for incident cognitive impairment diagnoses will be the steady state period + 4 months after.
The standardized cognitive assessment must occur during the steady state period and +/- 4 months of the incident diagnosis.
All standardized cognitive assessments will be counted.
See diagnosis list in PMID: 35124639 by the categories dementia, mild cognitive impairment, and other cognitive impairment.
Incident diagnoses are the first time that any of these diagnoses are documented in the medical record by any outpatient provider, using a 2 year look back window.
In addition, incident diagnoses of mild cognitive impairment and dementia will be counted even if an "other cognitive impairment diagnosis" was previously made.
|
During the 12-month steady state period
|
The rate of patients who have a referral to Geriatrics, Neurology or Psychiatry.
Time Frame: During the 12-month steady state period
|
Rate is out of all patients with an incident diagnosis, as defined in Outcome 2. The referral must occur within the 12-month steady state period + 4 months after, and within +/- 4 months of the incident diagnosis.
|
During the 12-month steady state period
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Katherine Possin, PhD, University of California, San Francisco
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 15, 2023
Primary Completion (Estimated)
September 14, 2026
Study Completion (Estimated)
September 14, 2026
Study Registration Dates
First Submitted
October 13, 2023
First Submitted That Met QC Criteria
October 13, 2023
First Posted (Actual)
October 19, 2023
Study Record Updates
Last Update Posted (Actual)
October 24, 2023
Last Update Submitted That Met QC Criteria
October 20, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- U01NS128913 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
Individual participant data will not be shared outside of Kaiser Permanente Southern California.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dementia
-
University of North Carolina, Chapel HillNational Institute on Aging (NIA)CompletedAlzheimer Dementia | Dementia Alzheimers | CaregiverUnited States
-
Temple UniversityRecruitingDementia | Mild Cognitive Impairment | Dementia, Vascular | Dementia, Mixed | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Dementia, MildUnited States
-
Hebrew SeniorLifeRecruitingAging | Alzheimer Dementia | Presenile Alzheimer DementiaUnited States
-
Temple UniversityRecruitingDementia | Alzheimer Disease | Mild Cognitive Impairment | Dementia, Vascular | Dementia, Mixed | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Dementia, MildUnited States
-
Cognito Therapeutics, Inc.Enrolling by invitationExtension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015)Cognitive Impairment | Alzheimer Disease | Mild Cognitive Impairment | Dementia Alzheimers | Dementia of Alzheimer Type | AD | Dementia, Mild | Dementia ModerateUnited States
-
National Tainan Junior College of NursingCompletedCognitive Impairment | Dementia, Mild | Dementia ModerateTaiwan
-
Karen RobertoNational Institute on Aging (NIA)RecruitingDementia | Dementia Alzheimers | Neuro-Degenerative Disease | Dementia of Alzheimer Type | Dementia SevereUnited States
-
University College, LondonNot yet recruitingDementia | Dementia, Vascular | Dementia, Mixed | Dementia With Lewy Bodies | Dementia of Alzheimer Type | Dementia Moderate | Dementia Severe | Dementia Frontal | DEM
-
University College, LondonThe University of Hong KongUnknownDementia | Dementia, Vascular | Dementia, Mixed | Dementia With Lewy Bodies | Dementia of Alzheimer Type | Dementia Moderate | Dementia Severe | Dementia Frontal
-
Karolinska InstitutetRegion Stockholm; KTH Royal Institute of TechnologyActive, not recruitingAlzheimer Dementia | Dementia DisordersSweden
Clinical Trials on TabCAT Brain Health Assessment
-
University of California, San FranciscoNational Institute on Aging (NIA); Kaiser Permanente WashingtonRecruitingDementia | Alzheimer DiseaseUnited States
-
Kaiser PermanenteUniversity of California, San FranciscoActive, not recruitingDementia | Alzheimer DiseaseUnited States
-
University of Dublin, Trinity CollegeUnknownBrain Health Retired Elite Athletes
-
Yale UniversityNational Institute on Aging (NIA)CompletedDelirium | Cognitive Impairment | Dementia | Emergency CareUnited States
-
Washington University School of MedicineCompletedDementia | Frontotemporal Dementia | Dementia Alzheimers | Pick's Disease With DementiaUnited States
-
BaycrestCompletedDementia | Mild Cognitive Impairment | Dementia Prevention | Subjective Cognitive Impairment | Pre-dementiaCanada
-
University Health Network, TorontoCompleted
-
Brigham and Women's HospitalEnrolling by invitationMild Cognitive Impairment | Subjective Cognitive Decline | Dementia, Mild | At Risk for Cognitive DeclineUnited States
-
Posit Science CorporationYMCA of San FranciscoRecruitingDementia | Alzheimer DiseaseUnited States
-
Pennington Biomedical Research CenterCompletedCognitive Dysfunction | AgingUnited States